Oleolive Inc was awarded funding from the National Cancer Institute to study a drug to treat brain cancer.

Oleolive’s phase 1 STTR grant application entitled “Chemosensitization of Glioblastoma by OL-TL1” was approved for funding. Glioblastoma (GBM) has poor clinical outcomes due to therapy-resistant tumor cells that lead to recurrence; therefore, therapeutic strategies that enhance tumor cell chemosensitivity are essential for improved patient outcomes. This proposal will evaluate if OL-TL1, an FDA-approved, well-characterized repurposable drug with good brain penetration and favorable safety metrics, increases sensitization of GBM tumor cells to chemotherapy. This project could lead to a therapeutic strategy to extend survival times for GBM patients. This is a joint effort between the Mayo Clinic and Oleolive.